BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $133.42, a high estimate of $155.00, and a low estimate of $110.00. A negative shift in sentiment is evident ...

Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and ...

A high-level meeting took place at the Ministry of Health of the Republic of Azerbaijan with a delegation led by Dmitry Kozenkov, Pfizer’s Head for the Caucasus, Central Asia, and Mongolia, Azernews ...

BioNTech ADR BNTX saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 73. Please ...

BioNTech is buying fellow German firm CureVac for approximately $1.25 billion as the COVID-19 vaccine maker moves to expand into cancer treatments. For each CureVac share they own, investors will get ...

BioNTech (BNTX 3.59%) is the lesser-known member of the pair -- which also includes Pfizer -- that developed and marketed Comirnaty, one of the leading coronavirus vaccines on the market.

Moderna claims Pfizer-BioNTech’s COVID vaccine infringes on patents it filed between 2010 and 2016 covering its mRNA technology. New strain in Calif. Get the USA TODAY app Start the day smarter ...

MAINZ, Germany, November 4, 2024-- BioNTech SE today reported financial results for the three and nine months ended September 30, 2024 and provided an update on its corporate progress. Ugur Sahin ...

BioNTech acquires Biotheus for $800 million plus milestone payments, securing global rights to BNT327/PM8002 and expanding its oncology and R&D presence in China.